Financial statements Norsa Pharma

Balance sheet of Norsa Pharma

Company age:
Age:
10 y. 11 m. 30 d.
Share capital:
Share capital:
5 000 PLN
Profit and loss statement Balance Cash flow Profitability

Balance sheet data of NORSA PHARMA

Year
2018
2019
2020
2021
2022
2023
2024
Total assets 2 488 004,31 3 317 602,75 3 971 219,25 3 661 477,06 4 202 379,30 5 893 338,80 13 581 001,93
A. Fixed assets 1 644 609,66 2 242 845,66 2 089 536,40 1 646 144,50 1 177 817,50 709 490,50 379 234,43
B. Current assets 843 394,65 1 074 757,09 1 881 682,85 2 015 332,56 3 024 561,80 5 183 848,30 13 201 767,50
C. Share capital contributions (basic funds) 0,00 0,00 0,00 0,00 0,00 0,00 0,00
D. Own shares (stocks) 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Total liabilities 2 488 004,31 3 317 602,75 3 971 219,25 3 661 477,06 4 202 379,30 5 893 338,80 13 581 001,93
A. Equity 873 209,18 1 313 386,61 1 550 988,25 2 181 988,58 2 963 367,39 4 976 638,58 11 335 674,49
B. Liabilities and provisions for liabilities 1 614 795,13 2 004 216,14 2 420 731,00 1 479 488,48 1 239 011,91 916 700,22 2 245 327,44
I. Long-term liabilities 85 000,00 - - - - 0,00 0,00
II. Short-term liabilities 443 569,32 - - - - 435 823,70 2 104 325,60
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
  • Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
  • Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
  • Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
  • Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
  • Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
  • Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.